Handling TBC, Biofarma Group Collaborates With Sinopharm China Pharmacy

ANTARA/HO-Biofarma Group

JAKARTA - The Holding of BUMN Pharmacy Biofarma Group supports the total solution to the prevention of Tuberculosis (TBC) by collaborating with Chinese pharmaceutical company Sinopharm.

This was realized through the signing of a Global Co-Development Partnership on Innovative Tuberculosis Treatment which was carried out on May 26, 2023 in Beijing, China.

Deputy Minister I of BUMN Pahala Nugraha Mansury said Indonesia is the country with the second highest prevalence TB in the world. Related to this, Biofarma Group has shown support and solutions related to TB handling.

"The Biofarma Group, as a state-owned pharmaceutical company, has shown support and solutions in dealing with TB through diagnostics, prevention with vaccines and treatment with pharmaceutical products," Pahala said as quoted by ANTARA, Thursday, June 1.

He also reminded that the collaboration between Biofarma Group and Sinopharm has been established for a long time since 2020. Most recently in early 2023, Kimia Farma and Sinopharm's subsidiaries have also signed an MoU related to the development of medicinal raw materials (BBO) and traditional Chinese medicine (TCM).

Pahala hopes that both parties can continue to collaborate in realizing the development of innovative global-scale products, including those related to TB treatment.

Meanwhile, Bio Farma's Director of Business Research and Development Yuliana Indriati said that the collaboration would produce effective TB treatment innovations.

According to him, Bio Farma and Sinopharm collaborate in the development of drug TB-resistance treatments, with lower side effects and efficacy as evidenced by clinical permits in several countries.

"Bio Farma and Sinopharm are working together to become global supply in TB prevention and treatment supported by clinical trial data and production processes in accordance with international provisions," said Yuliana.